This study is for patients aged 4 weeks to 75 years who have had a stem cell transplant for certain blood cancers (like AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, or CML) and are experiencing graft failure or low graft function. It tests a process called CD34 selection using the Automated CliniMACS Prodigy. This process isolates specific stem cells (CD34 selected hematopoietic stem cells) before they are given to you. The goal is to reduce serious complications like severe acute Graft-versus-Host Disease (GVHD) and extensive chronic GVHD, which can happen when the donor's immune cells attack your body. Researchers will also look at how well the donor cells are working in your body (donor chimerism). The study aims to make the stem cell preparation process more efficient. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 50 participants. The study does not specify a phase.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 6 years to measure severe acute GVHD, extensive chronic GVHD, and donor chimerism.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.